• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Cardiovascular

The following trials provide information to treat various types of cardiovascular diseases, both for ongoing and completed clinical trials.  For more information on this therapy area please click here.

There are a number of ways to help you find trial information.  By using these filters you can find (i) recruiting status, (ii) therapy area, (iii) product and/or (iv) phase of drug development.  You can use one or all filters to identify your specific needs.

When a trial completes the results are reported here no later than one year after completion – this is why you may sometimes find that a Report is unavailable when you are searching through ‘closed’ trials.

  • Expand All
  • Collapse All
  • Pages
  • Previous
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • Next
  • collapse Non-interventional study to assess reaching of cholesterol target values in patients treated with HMG-CoA reductase inhibitors in Croatia
  • collapse An Epidemiological Study Aimed to Record Standard Daily Practice in Managing Patients With Hypercholesterolemia
  • collapse A Randomised, Single-Blind, Placebo-Controlled, Single-Centre, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Interaction After Single Ascending Oral Doses of AZD6714 in Healthy Male Volunteers and Male Type II Diabetic Patients
  • collapse An Open-Label, Randomised, Placebo-Controlled, Two-Way Crossover, Phase I Single Centre Study in Type 2 Diabetes Mellitus Patients Treated with Metformin to Evaluate the Pharmacokinetics and Pharmacodynamics of Warfarin During Co-administration with AZD1656
  • collapse A Randomised, open, two-way Cross-over, Phase I Study to Evaluate the Response to Glucagon versus the spontaneous counter-regulatory response in T2DM Patients treated with AZD1656 and Metformin during hypoglycemia
  • collapse A Phase I, Multi-center, Open-label, Single Dose Study, to Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients With or Without Renal Impairment
  • collapse Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Fasting After Single Ascending Oral Doses of AZD5658 in Type 2 Diabetes Mellitus Patients
  • collapse A randomized, single-blind, placebo-controlled, phase I study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD1656 compared to placebo in T2DM patients treated with metformin and sulfonylurea
  • collapse A Randomised, Single-Blind, Placebo-Controlled, Phase IIA Study to Assess the Safety and Tolerability after Multiple Oral Doses of AZD1656 in Patients with Type 2 Diabetes Mellitus Treated with Metformin
  • collapse A Randomised, Two Way Cross-over, Single-Blind, Phase I Study to Evaluate 24-hr Glucose Profiles in Patients with T2DM when Dosed OD and BD on Top of Metformin for Four Days with AZD1656
  • Pages
  • Previous
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • Next
  • Expand All
  • Collapse All

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013